supernova bio, a bio-venture specializing in R&D, has developed innovative theragnostic therapies by creating gas-generating polymer nanoparticles that overcome the limitations of conventional chemotherapy and targeted therapies. While chemical approaches often lead to systemic side effects and resistance, supernova bio’s novel platform physically destroys diseased cells through targeted drug delivery, minimizing harm to healthy tissues. This innovative approach delivers therapeutic agents directly into target cells, where the gas disrupts the cell membrane, causing localized cell death. Using this technology, supernova bio has effectively reduced the volume of adipose tissue as well as tumors such as neuroblastoma and potentially liposarcoma. The gas generated within the target cells can be detected using ultrasound imaging, enabling precise diagnostic capabilities. The real-time monitorable nature of this treatment ensures precise therapeutic outcomes and enhanced safety.